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Abstract
As more HIV-infected people gain access to antiretroviral therapy (ART), monitoring HIV drug resistance (HIVDR) becomes
essential to combat both acquired and transmitted HIVDR. Studies have demonstrated dried blood spots (DBS) are a
suitable alternative in HIVDR monitoring using DBS collected on Whatman 903 (W-903). In this study, we sought to evaluate
two other commercially available filter papers, Ahlstrom 226 (A-226) and Munktell TFN (M-TFN), for HIVDR genotyping
following ambient temperature storage. DBS were prepared from remnant blood specimens collected from 334 ART
patients and stored at ambient temperature for a median time of 30 days. HIV-1 viral load was determined using NucliSENS
EasyQH HIV-1 v2.0 RUO test kits prior to genotyping of the protease and reverse transcriptase regions of the HIV-1 pol gene
using an in-house assay. Among the DBS tested, 26 specimens had a viral load $1000 copies/mL in all three types of filter
paper and were included in the genotyping analysis. Genotyping efficiencies were similar between DBS collected on W-903
(92.3%), A-226 (88.5%), and M-TFN (92.3%) filter papers (P = 1.00). We identified 50 DR-associated mutations in DBS collected
on W-903, 33 in DBS collected on A-226, and 48 in DBS collected on M-TFN, resulting in mutation detection sensitivities of
66.0% for A-226 and 88.0% for M-TFN when compared to W-903. Our data indicate that differences among filter papers may
exist at this storage condition and warrant further studies evaluating filter paper type for HIVDR monitoring.
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Introduction
The number of HIV-infected people on antiretroviral therapy
(ART) in low- and middle-income countries increased by more
than 20% from 2010 to 2011 and continues to increase
dramatically every year [1]. As the number of people on therapy
rises, there is a profound need for drug resistance (DR) monitoring
to combat both acquired and transmitted HIV drug resistance
(HIVDR). The standard specimen type for assessing HIVDR is
plasma, but multiple studies have been conducted verifying the
usefulness of dried blood spots (DBS) as a suitable alternative to
plasma [2–7]. The use of DBS for HIVDR monitoring is essential
in resource-limited countries, as plasma requires timely processing
and cold chain for storage and transportation.
Several studies have assessed DBS performance in HIVDR
genotyping under various storage temperatures and humidity
ranges with variable success (reviewed in [8,9]). It has been
suggested that extended storage of DBS at 4uC [10] or room
temperature (RT) [5] make genotyping of larger pol gene
fragments difficult. This has been found to be particularly true if
humidity is not controlled [11], but results still vary from study to
study (reviewed in [8,9]). For instance, Garcia-Lerma et al. found
that at 37uC with high humidity, DBS specimens were only stable
for one to two weeks [12]. However, Bertagnolio et al. tested DBS
specimens that had been stored at 37uC and with 85% humidity
for three months and found an amplification rate of 90% [13].
DBS specimens have proven to be stable at 220uC or below for
years in many different studies with consistent outcomes (reviewed
in [8,9]).
Most of the aforementioned studies utilized Whatman 903 filter
paper (W-903) to evaluate DBS. As mentioned previously, there
have been many studies comparing DBS to plasma, but only one
recent study by our laboratory has compared different types of
filter papers for HIVDR genotyping [14]. In this study, we
evaluated two other commercially available filter paper cards,
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Munktell TFN (M-TFN) and Ahlstrom grade 226 (A-226) and
compared them to Whatman 903 (W-903) filter paper [14]. We
found that DBS collected on these two filter paper cards
performed similarly to the ones collected on W-903 cards for
both HIVDR genotyping and viral load analysis when the DBS
cards were stored at 280uC. Storage at 280uC is the gold
standard for DBS storage [15], however is not always attainable in
many resource-limited settings. We therefore sought to assess the
impact of ambient temperature storage on HIV-1 viral load and
HIVDR analysis on DBS collected on M-TFN and A-226 filter
papers compared to W-903. The current study was part of a
project in our laboratory to increase the reservoir of commercially
available filter paper types, enhance competition of filter paper
suppliers and reduce the cost of filter papers in resource-limited
settings for HIVDR monitoring surveys using DBS specimens.
Materials and Methods
Specimen Collection and Storage
Specimen collection was described in detail previously [14].
Briefly, DBS specimens were collected from 334 HIV-positive
patients who were reported to be on highly active antiretroviral
therapy (HAART). DBS specimens were collected from remnant
whole blood specimens that were sent to the Nyangabgwe HIV
Reference Laboratory in Francistown, Botswana for clinical CD4
monitoring. Blood was stored at ambient temperature (media-
n = 31uC, range = 25–37uC; median humidity = 33%, range hu-
midity = 20–45%) for a median of 1 day (range #1–3 days) prior
to DBS preparation. No personal (including duration on HAART)
or demographic information was collected for this study. DBS
specimens were prepared by pipetting 100 mL of whole blood per
spot onto Whatman 903 (Whatman plc, Springfield Mill, UK),
Ahlstrom grade 226 (Ahlstrom Corporation, Helsinki, Finland),
and Munktell TFN (Munktell Inc, Raleigh, NC) filter papers.
Filter paper was allowed to dry overnight at ambient temperature
(median temperature = 31uC, median humidity = 33%). The next
day glassine paper was folded around each DBS card, and 10–25
cards were packaged in a Bitran bag with desiccant packs and a
humidity indicator card. Packaged DBS specimens were stored at
ambient temperature for a median of 30 days prior to being
received at the WHO-designated Specialized Drug Resistance
Laboratory at the Centers for Disease Control and Prevention
(CDC), Atlanta, GA, U.S. for testing. All specimens were stored at
-80uC upon arrival at CDC.
Ethics Statement
In accordance with United States regulations and international
guidelines, the protocol was approved by the Institutional Review
Board of the Ministry Health of Botswana. The anonymous testing
at CDC was determined as non-human subjects research by the
Associate Director for Science at the Center for Global Health,
CDC, Atlanta, GA, USA.
Nucleic Acid Extraction and HIV-1 VL Analysis
One DBS spot (100 mL) was cut out per specimen and placed in
2 mL of NucliSENSH lysis buffer (Biomeriuex, Durham, NC) for
30 min at room temperature with gentle rotation. Nucleic acid
was then extracted from all specimens using the NucliSENSH
EasyMagH (Biomeriuex, Durham, NC) automated extraction
system following the manufacturer’s instruction. Nucleic acid
was eluted in 25 mL of NucliSENSH Extraction Buffer 3 and stored
at 280uC until use. HIV-1 viral load was determined by the
NucliSENS EasyQH automated system using NucliSENS EasyQH
HIV-1 v2.0 RUO test kits (Biomeriuex, Durham, NC) following
the manufacturer’s instructions. The linear range of this assay is
500–21,000,000 copies/mL when a single DBS spot containing
100 mL of whole blood is used [16].
HIV-1 Drug-Resistance Genotyping
Genotyping of the protease and reverse transcriptase (RT)
regions of the HIV-1 pol gene was performed using a broadly
sensitive in-house genotyping assay described in detail previously
[7,17]. Briefly, a 1084 base-pair segment of the 59 region of the pol
gene was generated by RT-PCR and followed by nested PCR.
This fragment was purified, sequenced using the BigDyeH
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA), and analyzed on the ABI PrismTM 3730 Genetic
Analyzer (Applied Biosystems). Specimens that failed to amplify
were repeated once with an alternative RT-PCR primer to
account for potential mutations in the original primer binding site
following the standard practice in our laboratory. The ReCALL
software program was used to edit the raw sequences and generate
consensus sequences [18]. Phylogenetic analyses were conducted
with all the newly obtained sequences along with HIV-1 reference
sequences downloaded from the HIV database (http://www.hiv.
lanl.gov/content/sequence/NEWALIGN/align.html#ref) to en-
sure the absence of contamination and confirm clustering of
related samples using MEGA [19]. HIV drug-resistance mutations
and drug susceptibility profiles were determined using HIVdb and
HIValg programs deployed at the Stanford University Drug
Resistance Database (Palo Alto, CA). Unique sequences generated
in this study were submitted to GenBank under the following
accession numbers: KM387674-KM387706.
Statistical Analysis
Nucleotide sequence identity was calculated using the BioEdit
sequence alignment editor [20]. Statistical calculations were
performed using GraphPad Prism (version 5.0, GraphPad
Software, La Jolla, CA). Fisher’s exact test was used to compare
the genotyping efficiency and HIVDR mutation frequency of DBS
specimens collected on A-226 and M-TFN to the ones collected on
W-903 filter paper. Kappa Statistic was used to assess the
concordance between the test filter papers (A-226 and M-TFN)
and the gold standard (W-903) for HIVDR mutation detection;
values were categorized as poor (,0.40), good (0.4 to 0.75), or
excellent (.0.75) [21].
Results
HIV-1 pol Genotyping Efficiency
Due to viral load variability described previously [14] and the
lack of a plasma gold standard control, we limited our genotyping
analyses to only those specimens that had a viral load $
1,000 copies/mL in all three types of filter paper tested. Among
the 334 specimens analyzed, we identified 26 specimens that met
these criteria. Table 1 illustrates that the overall genotyping
efficiencies for these DBS specimens were 88.5% to 92.3% among
the three types of filter paper. Although W-903 and M-TFN filter
papers had higher genotyping rates than the A-226, there were no
statistically significant differences among the filter paper types
(p = 1.00). In addition, there were four specimens that had viral
load $1,000 copies/mL and failed to amplify or genotype in at
least one type of the filter papers (Table 2). Of these four
specimens: one specimen was not amplified in any type of the filter
papers, one was amplified but failed genotyping on W-903 only,
one specimen was amplified on W-903 but not the other two filter
papers, and one specimen failed amplification on A-226 only
(Table 2). Nucleotide sequence identity to W-903 filter paper was
DBS Collected on 3 Types of Filter Paper for HIVDR Monitoring
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similar between A-226 (98.960.8) and M-TFN (98.661.2)
(Table 1).
HIV Drug Resistance Mutation Frequency and Profiles
Accurate identification of drug resistance mutations is the most
important aspect of an HIVDR monitoring survey. To determine
whether filter paper type affected HIVDR mutation profiles and
whether identified differences resulted in significant changes to
drug susceptibility, we compared the HIVDR mutation profiles
between filter paper types for those 26 specimens that had VL $
1,000 copies/mL in all three types of filter paper. Overall, we
identified 50 nucleoside reverse transcriptase inhibitor (NRTI) and
non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations
in DBS collected on W-903, 33 in specimens collected on A-226,
and 48 in DBS collected on M-TFN (Table 2). Out of the 26
specimens analyzed, 18 displayed identical DR mutation profiles
between all three types of filter paper with nine having identical
HIVDR mutation profiles, eight having no HIVDR mutations
Table 1. Genotyping efficiency and nucleotide sequence identities of 26 DBS specimens with a VL $1000 copies/mL and collected
on W-903, A-226, and M-TFN filter papers.
W-903 A-226 M-TFN
Genotyping Efficiency 92.3% (24/26) 88.5% (23/26) 92.3% (24/26)
P-value* 1.00 1.00
Nucleotide Identity to W-903 (Mean ± SD#) 98.960.8 98.661.2
*:Fisher’s exact test; #SD: Standard deviation.
doi:10.1371/journal.pone.0109060.t001
Table 2. HIV drug resistance mutation Profiles of DBS specimens collected on W-903, A-226, and M-TFN filter papers.
W-903 A-226 M-TFN
Specimen # NRTI NNRTI NRTI NNRTI NRTI NNRTI
10 E138AE
23 No PCR Product No PCR Product No PCR Product
35* D67DN, K70R, M184V,
K219KQ
Y181C, M184V Y181C D67DN, K70KR,
M184MV, K219KQ,
Y181CY, H221HY
62 D67N, M184V L100I, K103N D67N, M184V L100I, K103N D67N, M184V, L100I, K103N
64 D67N, K70R, M184V,
T215F, K219Q
V106M, Y181C D67N, K70R, M184V,
T215F, K219Q
V106M, Y181C D67N, K70R, M184V,
T215F, K219Q
V106M, Y181C
69 V118I E138A V118I E138A V118I E138A
90 M184V K103N M184V K103N M184V K103N
155 K103KN K103KN K103KN
182 K103N, V106MV K103N, V106MV K103N, V106MV
183 M184V Y188L, K238N M184V Y188L, K238N M184V Y188L, K238N
255* M184MV
269 M41L, M184V, T215Y Y188L M41L, M184V,
T215Y
Y188L M41L, M184V, T215Y Y188L
280 D67G, M184V K103N, P225H D67G, M184V K103N D67DG, M184V,
T215IT
K103N, P225H
287 M184V V106M, V179D M184V V106M, V179D M184V V106M, V179D
317* D67DN, K70KR,
M184V, K219KQ
A98G, K103N M184V A98G, K103N
147 Genotyping Failed
295* K65R, D67N, Y115F V90I, K103N,
V106M
No PCR Product K65R, Y115F, K219R K103N, V106M
328 No PCR Product No PCR Product
Total # Mutations 50 33 48
HIV-1 drug resistance genotyping analyses of the pol region were performed for all the DBS specimens with a viral load $1,000 copies/mL and with all three types of
the filter papers using a broadly sensitive genotyping assay (N = 26). Drug resistance mutations against nucleoside reverse transcriptase inhibitors (NRTIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTIs) were identified using the HIVdb program, and HIV-1 drug resistance profiles were determined by the HIValg
program at the Stanford HIV Drug Resistance Database website. Discordant mutations that were identified in only one type of filter paper are shown in boldface type.
Specimens that had a difference in drug susceptibility ratings with one of the filter paper types are indicated by asterisk (*). Eight specimens with no mutations detected
in any of the filter paper types were excluded from the table.
doi:10.1371/journal.pone.0109060.t002
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detected, and one failing to amplify in all three filter paper types
(specimen 23) (Table 2). Four specimens had discordant HIVDR
profiles that led to differences in the drug susceptibility rating
(Table 2). Two of these discordant specimens were due to
mutations identified in W-903 filter paper but not in A-226 or
M-TFN; one was the result of mutations identified on W-903 and
M-TFN but not on A-226, and the fourth specimen had an
H221H/Y mixture that was detectable only in the specimen
collected on M-TFN. Two-by-two tables comparing HIVDR
mutation detection in A-226 and M-TFN to W-903 were
constructed using the International AIDS Society 2011 list of
NRTI and NNRTI HIVDR mutation sites [22]. These analyses
revealed an overall HIVDR mutation detection sensitivity of
66.0% for A-226 (P = 0.071) and 88.0% for M-TFN (P = 0.917)
when compared to DBS collected on W-903 (Table 3). Kappa
values illustrated excellent concordance between DBS collected on
A-226 (0.7960.05) and M-TFN (0.8960.03) compared to W-903
(Table 3).
Discussion
The objective of this study was to determine whether DBS
specimens collected on W-903, A-226, and M-TFN filter papers
and stored at ambient temperature performed similarly for HIV-1
drug resistance genotyping. Genotyping efficiencies were not
statistically different between the DBS specimens collected on A-
226 (p = 1.00) and M-TFN (p = 1.00) compared to those collected
on W-903 (Table 1). Out of 26 specimens analyzed, four had
discordant HIVDR profiles that resulted in differences in drug
susceptibility between one or two of the filter paper types
(Table 2). Of the three types of filter paper, DBS collected on
A-226 and stored at ambient temperature appeared to be the least
sensitive for HIVDR genotyping (Tables 2-3), although statistical
significance was not reached, likely due to the small sample size.
This study was limited by a small sample size and the lack of a
true gold standard plasma specimen. This study utilized remnant
specimens from CD4 monitoring and the specimens were
therefore not available for plasma separation until a median of 1
days (range ,1-3 days) after collection. We felt that specimen
integrity was compromised due to the duration and temperature
(median = 31uC) of storage and opted to exclude these plasma
specimens from the study. To compensate for the absence of a
gold standard specimen, we limited our analysis to those specimens
that had a detectable VL (defined as viral load $1,000 copies/mL)
in all three types of filter paper to help standardize the analyses. In
doing so, we were only able to analyze 26 specimens and thus
cannot make definitive recommendations regarding the perfor-
mance of filter papers for HIV drug resistance analysis.
The genotyping efficiencies illustrated in Table 1 were similar
for all three types of filter paper, indicating that there were no
differences in maintaining HIV-1 RNA integrity between the filter
papers. The efficiencies achieved in this study of 92.3% for W-903,
88.5% for A-226 and 92.3% for M-TFN were in agreement with
previous studies using this particular genotyping assay on DBS
specimens. These previous studies demonstrated amplification/
genotyping efficiencies of 77.8% [14], 80.6% [14], 89.5% [2],
93.3% [14], 95.8% [7] and 100% [6]. Despite similar genotyping
efficiencies for all three types of filter paper, we observed a bias in
the detection of drug resistance mutations in DBS collected on A-
226 filter paper. DBS collected on A-226 detected 33 HIVDR
mutations, compared to 50 from W-903 and 48 from M-TFN
(Table 2). Furthermore, there was an even distribution of false-
positive and false-negative mutations detected in M-TFN
compared to W-903 (Table 3). This distribution was skewed in
the analysis of A-226 with zero false-positive and 17 false-negative
mutations detected compared to W-903 (Table 3). This bias was
not evident in a previous study comparing DBS collected on the
three types of filter paper and stored at -80uC [14]. These data
indicate that in this study, DBS collected on A-226 filter paper and
stored at ambient temperature did not perform as well as DBS
collected on W-903 and M-TFN for HIVDR genotyping analysis.
The limitations of this study prevent us from making
overarching conclusions regarding the similarity or differences of
DBS collected on A-226, M-TFN, and W-903 filter papers and
stored at ambient temperature. Our data do however indicate that
differences may exist at this storage condition and warrant further
studies comparing different types of filter paper. Such studies are
critical for expanding the availability of filter paper for DBS
collection for HIVDR monitoring surveys and will likely lead to
decreased costs for the future HIVDR monitoring surveys.
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